Mar 23, 18 · Ilumya marks the second interleukin23 (IL23) inhibitor to gain FDA approval within the past year, following the approval of J&J's Tremfya (guselkumab) in July 17 Share Article On March 21, the FDA approved Sun Pharma's Ilumya (tildrakizumab) for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidatesJun 03, · Ustekinumab is a human monoclonal antibody directed against IL12 and IL23, thereby interfering with Tcell differentiation and activation and subsequent cytokine cascades ItNov 25, · Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective However, in those patients who failed one or more of the abovecited drugs, reallife data on the effectiveness of switching to one anti
Il 23 Antagonists In The Treatment Of Plaque Psoriasis Dermatology Advisor
